Could an already approved drug cut down on opioid use after surgery?
A pilot study conducted by Medical University of South Carolina researchers has found that an FDA-approved drug called NAC could be useful for reducing the need for opioids after spinal surgery
IMAGE:
AN ASTROCYTE, A TYPE OF NON-NEURONAL CELL, IN THE RODENT CORTEX. THE OUTER BOUNDARY OF THE CELL IS SHOWN IN YELLOW; THE CELL “SKELETON” IN TEAL.
view moreCREDIT: MEDICAL UNIVERSITY OF SOUTH CAROLINA. IMAGE COURTESY OF DR. MICHAEL D. SCOFIELD OR CONTACT DR. SCOFIELD FOR PERMISSION.
Researchers in the Department of Anesthesia and Perioperative Medicine at the Medical University of South Carolina (MUSC) have found that an FDA-approved drug may help to decrease pain after surgery. In the pilot study published in Pain Management, spinal surgery patients who received N-acetylcysteine (NAC) during surgery in addition to standard pain control treatments reported lower pain scores and requested fewer opioids after surgery than patients given a placebo.
Opioids are often given for a short time after surgery to treat pain. Although effective, their potency can wain and addictive potential can be dangerous without careful supervision by a health care provider. As such, physicians welcome the opportunity to limit opioid use in managing pain.
“Can we stop giving opiates completely? Likely not. Can we decrease the amount patients need? We should try,” said Sylvia Wilson, M.D., the Jerry G. Reves Endowed Chair in Anesthesia Research in the Department of Anesthesia and Perioperative Medicine and a principal investigator of the study.
Wilson has worked for years on efforts to improve pain management and limit opioid usage after surgical operations. As it turns out, a collaboration with a basic scientist within her own department could offer a solution.
A productive partnership
Wilson began to work closely with Michael Scofield, Ph.D., the Jerry G. Reves Endowed Chair in Basic Science Anesthesiology Research and a senior author of the published study. Scofield has conducted laboratory research on NAC, an anti-inflammatory drug that is used to treat acetaminophen poisoning, mushroom poisoning and liver damage. Researchers, such as Scofield, have also studied its effects on the nervous system, especially in the areas of addiction and pain perception. Wilson’s clinical goals and Scofield’s research on NAC made them ideal collaborators.
“This project is really an elegant synthesis of basic science and clinical research, using things we find have efficacy in the laboratory and taking them to the clinic,” said Scofield.
Wilson believes that partnerships between physicians and basic scientists can spur clinical advances. She credits the supportive environment within the department fostered by Chairman Scott Reeves, M.D., and former College of Medicine Dean Jerry G. Reves, M.D., for making such partnerships possible.
Promising trial insights
The research team chose spinal surgery patients for its pilot study because these patients often experience chronic pain before surgery and are more likely to be exposed to higher levels of opioids before, during and after surgery. During surgery, patients received a standard regimen of anesthesia in addition to a dose of NAC or a saline infusion. Information on patients’ pain and opioid consumption was then collected.
In the 48 hours after surgery, patients who were administered NAC via IV infusion (150 mg/kg) received 19% fewer opioid doses on average than patients who received saline. NAC patients also reported lower pain scores and took a longer time to request pain medication after their surgery than the saline patients. The researchers were especially encouraged to see that the beneficial effect seemed to last longer than the NAC was expected to remain in the body.
“We’ve seen the impact of giving this medication persisting, and I think that’s significant,” said Wilson. “We’re not seeing a rebound effect when that medication wears off.”
This extended effect on pain perception mirrored previous findings from Scofield’s laboratory research.
“For heroin addiction, we had seen in NAC preclinical studies that protection against relapse vulnerability is long lasting,” said Scofield. “Certainly, the hope is that it’s something that has a long duration.”
Looking to the future
Next, the research team wants to investigate whether the findings can be translated to other procedures. They are currently enrolling patients undergoing minimally invasive hysterectomies in a larger trial. As more patients are enrolled, the researchers will be able to conduct more in-depth statistical tests to improve their understanding of the effects of NAC on surgery-associated pain. This will help them to set the stage for future clinical trials of NAC during surgery.
“To change practice, you need many large clinical trials with different settings, different types of surgeries to show that you’re going to cause benefit, not harm,” said Wilson. “We want to show good clinical efficacy, but also safety in that situation.”
# # #
About MUSC
Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,200 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 900 residents and fellows in its health system. MUSC brought in more than $298 million in research funds in fiscal year 2022, leading the state overall in research funding. MUSC also leads the state in federal and National Institutes of Health funding, with more than $220 million. For information on academic programs, visit musc.edu.
As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 16 hospitals (includes owned and equity stake), with approximately 2,700 beds and four additional hospital locations in development; more than 350 telehealth sites and connectivity to patients’ homes; and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
MUSC has a total enterprise annual operating budget of $5.1 billion. The nearly 26,000 MUSC family members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research, and patient care.
Michael Scofield, Ph.D. (left) is the Jerry G. Reves Endowed Chair in Basic Science Anesthesiology Research at the Medical University of South Carolina. Sylvia Wilson, M.D. (right) is the Jerry G. Reves Endowed Chair in Anesthesia Research at MUSC.
CREDIT
Medical University of South Carolina. Photograph by Sarah Pack
JOURNAL
Pain Management
METHOD OF RESEARCH
Randomized controlled/clinical trial
SUBJECT OF RESEARCH
People
ARTICLE TITLE
The impact of intraoperative N-acetylcysteine on opioid consumption following spine surgery: a randomized pilot trial
No comments:
Post a Comment